8-K current report · filed Jul 8, 2026

Tarsus Pharmaceuticals, Inc. (TARS) 8-K Current Report: July 8, 2026

Item 8.01Item 3.02Item 1.01TARS overview

Short answer

Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 8.01 (Other Events), Item 3.02 (Unregistered Sales of Equity Securities), Item 1.01 (Entry into a Material Definitive Agreement). Tarsus acquired iRenix Medical on July 6, 2026, making iRenix a wholly owned subsidiary.

Tarsus Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Tarsus acquired iRenix Medical on July 6, 2026, making iRenix a wholly owned subsidiary
  • Upfront consideration: $37.5M cash, subject to adjustments, plus 607,093 Tarsus shares
  • Additional milestone payments up to $490M tied to regulatory approvals and commercial sales
  • Future revenue-sharing obligations: low-to-mid single-digit percentage of net sales for certain products
  • Escrow funding supports indemnification obligations and potential merger consideration adjustments

Item 3.02 · Unregistered Sales of Equity Securities

  • Stock Consideration issued privately to eligible iRenix stockholders as acquisition-related equity consideration
  • Offering limited to accredited investors under Securities Act Section 4(a)(2) and Regulation D exemptions
  • Exemption avoids public registration, but creates potential future dilution for existing Tarsus shareholders

Item 8.01 · Other Events

  • Tarsus completed an acquisition on July 8, 2026
  • Transaction details and strategic rationale contained in Exhibit 99.1
  • Completion marks a material corporate event potentially affecting operations and financial outlook

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tarsus Pharmaceuticals, Inc. 8-K filings

Get the next TARS 8-K as it lands

Follow TARS for push alerts, or ask the research agent what this filing means.